Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
Date:7/29/2009

CRANBURY, N.J., July 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce second quarter 2009 financial results after the regular close of markets on Wednesday, August 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.

Interested participants and investors may access the conference call at 5 p.m. EDT by dialing 877-591-4949 (U.S./Canada) or 719-325-4889 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4035217.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
2. Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date
3. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
4. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
5. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Amicus Therapeutics Announces Change to Board of Directors
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
10. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
11. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
(Date:2/3/2016)... , Feb. 3, 2016 Ascendis Pharma A/S ... that applies its innovative TransCon technology to address significant ... an upcoming investor conference.Event:2016 Leerink Partners Global Healthcare Conference ... , Wednesday, February 10, 2016 Time:  , 11:55am ... . --> An audio webcast of this ...
(Date:2/3/2016)... N.J. , Feb. 3, 2016 ... totaling more than $1 million for researchers in ... working on health-related research that demonstrates exciting potential. ... round of funding for the New Jersey Health Foundation ... faculty members at these educational institutions— Princeton University, ...
(Date:2/3/2016)... ... 03, 2016 , ... ProMIS Neurosciences is currently in the ... misfolded, propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans ... Following on from the first misfolded Amyloid beta target announced on Nov. 12, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):